| Haley Alexis Marabi, OTR | |
|
475 Northern Blvd Ste 19, Great Neck, NY 11021-4802 | |
| (516) 829-0030 | |
| Not Available |
| Full Name | Haley Alexis Marabi |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 475 Northern Blvd Ste 19, Great Neck, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043933328 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 027187 (New York) | Primary |
| Provider Name | Fox Rehabilitation Physical Therapy Services Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1174560650 PECOS PAC ID: 1355395179 Enrollment ID: O20061023000060 |
News Archive
A recent study by researchers from the Netherlands highlights that the introduction of vaccination programs against coronavirus disease 2019 (COVID-19) to adolescents and children may reduce infection rates and severe disease outcomes – both in these age groups and in the population as a whole. The paper is currently available on medRxiv* preprint server while it undergoes peer review.
Virco Lab, Inc., the U.S. affiliate of Virco BVBA, today announced the launch of AVIGA and AVIGA REPORTER. AVIGA is a web-based electronic health record (EHR) solution with HIV/AIDS disease-specific functionality and AVIGA REPORTER is a web-based, data-reporting module designed specifically for the purposes of conducting HIV/AIDS research and providing reporting capabilities.
VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against the following question: "Based on the current available data, do you believe the overall benefit-risk assessment of PHEN/TPM (QNEXA) is favorable to support its approval for the treatment of obesity in individuals with a BMI > 30 kg/m2 or > 27 kg/m2 with weight-related co-morbidities?" The three co-morbidities included hypertension, diabetes and dyslipidemia.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
› Verified 6 days ago
| Provider Name | Reddy Care Physical And Occupational Therapy Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1477052967 PECOS PAC ID: 6103176987 Enrollment ID: O20180829003100 |
News Archive
A recent study by researchers from the Netherlands highlights that the introduction of vaccination programs against coronavirus disease 2019 (COVID-19) to adolescents and children may reduce infection rates and severe disease outcomes – both in these age groups and in the population as a whole. The paper is currently available on medRxiv* preprint server while it undergoes peer review.
Virco Lab, Inc., the U.S. affiliate of Virco BVBA, today announced the launch of AVIGA and AVIGA REPORTER. AVIGA is a web-based electronic health record (EHR) solution with HIV/AIDS disease-specific functionality and AVIGA REPORTER is a web-based, data-reporting module designed specifically for the purposes of conducting HIV/AIDS research and providing reporting capabilities.
VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against the following question: "Based on the current available data, do you believe the overall benefit-risk assessment of PHEN/TPM (QNEXA) is favorable to support its approval for the treatment of obesity in individuals with a BMI > 30 kg/m2 or > 27 kg/m2 with weight-related co-morbidities?" The three co-morbidities included hypertension, diabetes and dyslipidemia.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
› Verified 6 days ago
| Provider Name | Central Occupational Therapy Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1063199552 PECOS PAC ID: 8224483615 Enrollment ID: O20231004001902 |
News Archive
A recent study by researchers from the Netherlands highlights that the introduction of vaccination programs against coronavirus disease 2019 (COVID-19) to adolescents and children may reduce infection rates and severe disease outcomes – both in these age groups and in the population as a whole. The paper is currently available on medRxiv* preprint server while it undergoes peer review.
Virco Lab, Inc., the U.S. affiliate of Virco BVBA, today announced the launch of AVIGA and AVIGA REPORTER. AVIGA is a web-based electronic health record (EHR) solution with HIV/AIDS disease-specific functionality and AVIGA REPORTER is a web-based, data-reporting module designed specifically for the purposes of conducting HIV/AIDS research and providing reporting capabilities.
VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against the following question: "Based on the current available data, do you believe the overall benefit-risk assessment of PHEN/TPM (QNEXA) is favorable to support its approval for the treatment of obesity in individuals with a BMI > 30 kg/m2 or > 27 kg/m2 with weight-related co-morbidities?" The three co-morbidities included hypertension, diabetes and dyslipidemia.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Haley Alexis Marabi, OTR 475 Northern Blvd Ste 27, Great Neck, NY 11021-4802 Ph: (516) 829-0030 | Haley Alexis Marabi, OTR 475 Northern Blvd Ste 19, Great Neck, NY 11021-4802 Ph: (516) 829-0030 |
News Archive
A recent study by researchers from the Netherlands highlights that the introduction of vaccination programs against coronavirus disease 2019 (COVID-19) to adolescents and children may reduce infection rates and severe disease outcomes – both in these age groups and in the population as a whole. The paper is currently available on medRxiv* preprint server while it undergoes peer review.
Virco Lab, Inc., the U.S. affiliate of Virco BVBA, today announced the launch of AVIGA and AVIGA REPORTER. AVIGA is a web-based electronic health record (EHR) solution with HIV/AIDS disease-specific functionality and AVIGA REPORTER is a web-based, data-reporting module designed specifically for the purposes of conducting HIV/AIDS research and providing reporting capabilities.
VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against the following question: "Based on the current available data, do you believe the overall benefit-risk assessment of PHEN/TPM (QNEXA) is favorable to support its approval for the treatment of obesity in individuals with a BMI > 30 kg/m2 or > 27 kg/m2 with weight-related co-morbidities?" The three co-morbidities included hypertension, diabetes and dyslipidemia.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
› Verified 6 days ago
Mark Guzman, OTR/L Occupational Therapist Medicare: May Accept Medicare Assignments Practice Location: 475 Northern Blvd Ste 19, Great Neck, NY 11021 Phone: 516-829-0030 | |
Madeline E Sieber, Occupational Therapist Medicare: May Accept Medicare Assignments Practice Location: 475 Northern Blvd Ste 19, Great Neck, NY 11021 Phone: 516-829-0030 Fax: 516-466-7723 | |
Grace Lisandrelli, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 475 Northern Blvd Ste 19, Great Neck, NY 11021 Phone: 516-829-0030 | |
Katherine Susan Bowles, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 475 Northern Blvd, Great Neck, NY 11021 Phone: 516-829-0030 | |
Catherine Chang, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 833 Northern Blvd Suite 235, Great Neck, NY 11021 Phone: 516-288-3400 Fax: 516-288-3410 | |
Regina Kakuriyeva, OTR/L Occupational Therapist Medicare: May Accept Medicare Assignments Practice Location: 475 Northern Blvd Ste 19, Great Neck, NY 11021 Phone: 516-829-0030 Fax: 516-466-7723 | |
Rachel Ahdoot, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 20 Fir Dr, Great Neck, NY 11024 Phone: 516-225-8905 |